Semin Vasc Med 2003; 03(2): 097-106
DOI: 10.1055/s-2003-40667
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Antithrombotic Drugs in Vascular Medicine: A Historical Perspective

Karsten Schrör
  • Institut für Pharmakologie und Klinische Pharmakologie, UniversitätsKlinikum Düsseldorf, Düsseldorf, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. Juli 2003 (online)

ABSTRACT

Many new antithrombotic and antiplatelet drugs have been developed that have markedly improved prophylaxis and treatment of thrombotic diseases. Clopidogrel, a potent new antiplatelet compound, is the first clinical alternative to aspirin for long-term oral treatment and prevention of arterial thrombosis. Another new, exciting category of antiplatelet compounds is the GPIIb/IIIa-antagonists, the first antiintegrins in clinical use and the most potent inhibitors of platelet aggregation. Low molecular weight heparins (LMWHs) are the quantitatively dominating group of new antithrombotics, which has replaced unfractionated heparin for the prophylaxis and treatment of venous thromboembolism. Current clinical evidence suggests that LMWHs might replace unfractionated heparin for the treatment and prophylaxis of atherothrombotic complications in acute coronary syndromes in the near future. Fondaparinux is the first synthetic pentasaccharide and a selective inhibitor of factor Xa with exciting clinical data; it could become an alternative LMWH for prophylaxis of arterial and venous thromboembolism in high-risk patients. The field of oral thrombin inhibitors is still dominated by the coumarins. However, much effort is being undertaken to develop new orally active drugs from which ximelagatran is currently the leading compound with a predicted better safety and efficacy profile. Alternatively, inhibitors of factor VIIa might be of interest as well. Open questions include, in particular, the possible individualization of drug therapy in dependence on the kind of disturbed platelet function or blood hypercoagulability, respectively.

REFERENCES

  • 1 Esmon C T. Regulation of blood coagulation.  Biochim Biophys Acta . 2000;  1470 349-360
  • 2 Ross R. Atherosclerosis-an inflammatory disease.  N Engl J Med . 1999;  340 115-126
  • 3 Taubman M B, Fallon J T, Schecter A D. Tissue factor in the pathogenesis of atherosclerosis.  Thromb Haemost . 1997;  78 200-204
  • 4 Kulkarni S, Dopheide S M, Yap C L. A revised model of platelet aggregation.  J Clin Invest . 2001;  105 783-791
  • 5 Zaman A G, Herlft G, Worthley S G, Badimon J J. The role of plaque rupture and thrombosis in coronary artery disease.  Atherosclerosis . 2000;  149 251-266
  • 6 Hirsh J, Dalen J E, Anderson D R. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest . 1998;  114 (suppl 6) 445S-460S
  • 7 Marmur J D, Rossikhina M, Guha A. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury.  J Clin Invest . 1993;  91 2253-2259
  • 8 Davies M J, Thomas A C. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina.  Br Heart J . 1985;  53 363-373
  • 9 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.  Semin Thromb Haemost . 1997;  23 349-356
  • 10 ISIS-2. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.  Lancet . 1988;  2 349-360
  • 11 Meade T W. for the Medical Research Council's General Practice Research Famework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.  Lancet . 1998;  351 233-241
  • 12 Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients.  Br Med J . 1994;  308 81-106
  • 13 Weber A-A, Zimmermann K C, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.  Lancet . 1999;  353 900
  • 14 Zimmermann N, Kienzle P, Weber A-A, Winter J, Gams E, Schrör K, Hohlfeld T. Aspirin resistance after coronary artery bypass grafting.  J Thor Cardiovasc Surg . 2001;  121 982-984
  • 15 Patrono C, Coller B, Dalen J E. Platelet-active drugs. The relationship among dose, effectiveness, and side effects.  Chest . 2001;  119 39S-63S
  • 16 Weber A-A, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: a typological approach.  Platelets . 2002;  13 37-40
  • 17 Mukherjee D, Nissen S E, Topol E J. Risk of cardiovascular events associated with selective COX-2 inhibitors.  JAMA . 2001;  286 954-959
  • 18 McAdam B F, Catella-Lawson F, Mardini I A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2-the human pharmacology of a selective inhibitor of COX-2.  Proc Natl Acad Sci USA . 1999;  96 272-277
  • 19 Belton O, Byrne D, Kearney D. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.  Circulation . 2000;  102 840-845
  • 20 Schrör K. Ticlopidine and clopidogrel. In: Ferguson JJ, Chronos NAF, Harrington RA, eds. Antiplatelet Therapy in Clinical Practice London: Martin Dunitz; 2000: 93-111
  • 21 The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med   2001;  345 494-502
  • 22 Gent M. A randomised, blind, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet . 1996;  348 1329-1339
  • 23 Hermann A, Rauch B H, Braun M, Schrör K, Weber A-A. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression and inhibition by clopidogrel.  Platelets . 2001;  12 74-82
  • 24 Henn V, Steinbach S, Büchner K. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.  Blood . 2001;  98 1047-1054
  • 25 Nurden A T, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors. Basic and clinical aspects.  Arterioscler Thromb Vasc Biol . 1999;  19 2835-2840
  • 26 Schrör K (Hrsg). Abciximab-Erstes klinisch eingeführtes Antiintegrin zur Hemmung der Thrombozytenaggregation. Frechen: Dr. Schrör Verlag 2000
  • 27 Tcheng J E, Ellis S G, George B S. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.  Circulation . 1994;  90 1757-1764
  • 28 Reverter J C, Béguin S, Kessels H, Kumar R, Hemker H C, Coller B S. Inhibition of platelet-mediated, tissue factor induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis.” .  J Clin Invest . 1996;  98 863-874
  • 29 Coller B S. Binding of abciximab to αVβ3 and activated αMβ2 receptors: with a review of platelet-leukocyte interactions.  Thromb Haemost . 1999;  82 326-335
  • 30 Tanguay J-F. Do differences in pharmacology of platelet GPIIb/IIIa inhibitors affect clinical outcomes?.  Eur Heart J . 1999;  1 (suppl E) E27-E35
  • 31 Tcheng J E. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.  Am J Cardiol . 1999;  83 7E-11E
  • 32 Topol E-J, Moliterno D-J, Herrmann H-C. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutanous coronary revascularization.  N Engl J Med . 2001;  344 1888-1894
  • 33 Montalescot G, Barragan P, Wittenberg O. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.  N Engl J Med . 2001;  344 1895-1903
  • 34 Peter K, Schwarz M, Ylanne J. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.  Blood . 1998;  92 3240-3249
  • 35 Weber A-A, Schrör K. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.  Blood . 2001;  98 1619-1621
  • 36 Chew D P, Bhatt D L, Sapp S, Topol E J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. A meta-analysis of phase III multicenter randomized trials.  Circulation . 2001;  103 201-206
  • 37 Aithal G P, Day C P, Kesteven P JL, Daly A K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.  Lancet . 1999;  353 717-719
  • 38 Hauptmann J, Stürzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside.  Thromb Res . 1999;  93 203-241
  • 39 Gustafsson D, Nystroem J-E, Carlsson S. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.  Thromb Res . 2001;  101 171-181
  • 40 Van Aken H, Bode C H, Darius H. Anticoagulation: the present and future.  Clin Appl Thromb Haemost . 2001;  7 195-204
  • 41 Goodman S, Bigonzi F, Radley D, for the ESSENCE Group. One-year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction) (abstract).  Eur Heart J . 1998;  50 P477
  • 42 Hart R G, Benavente O, Pearce L A. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis.  Cerebrovasc Dis . 1999;  9 215-217
  • 43 Schrör K. Combination of oral anticoagulant and platelet inhibitor drugs: focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement.  Eur Heart J . 2001;  3 (suppl Q) Q54-Q59
  • 44 Rai R, Sprengeler P A, Elrod K C, Young W B. Perspectives on factor Xa inhibition.  Curr Med Chem . 2001;  8 101-119
  • 45 Tanabe K, Morishima Y, Shibutani T. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.  Thromb Haemost . 1999;  81 828-834